

1 Rare Genomic Copy Number Variants Implicate New Candidate Genes for Bicuspid Aortic
2 Valve

3

4 **Authors:** Steven G. Carlisle¹, Hasan Albasha², Hector Michelena³, Anna Sabate-Rotes⁴, Lisa
5 Bianco⁴, Julie De Backer⁵, Laura Muiño Mosquera⁶, Anji T. Yetman⁷, Malenka M Bissell⁸,
6 Maria Grazia Andreassi⁹, Ilenia Foffa⁹, Dawn S. Hui¹⁰, Anthony Caffarelli¹¹, Yuli Y. Kim¹²,
7 Dong-Chuan Guo¹, Rodolfo Citro¹³, Margot De Marco¹⁴, Justin T. Tretter¹⁵, Kim L. McBride¹⁶,
8 [&]EBAV Investigators, [&]BAVCon Investigators, Dianna M. Milewicz¹, Simon C. Body¹⁷,
9 Siddharth K. Prakash¹

10

11 ¹Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston,
12 Texas.

13 ²UCD School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

14 ³Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

15 ⁴Department of Pediatric Cardiology, Hospital Vall d'Hebron, Facultad de Medicina, Universidad
16 Autònoma Barcelona, Barcelona, Spain.

17 ⁵Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium; VASCERN HTAD European
18 Reference Centre, Belgium; Department of Pediatrics, Division of Pediatric Cardiology, Ghent University
19 Hospital, Ghent, Belgium; Department of Cardiology, Ghent University Hospital, Ghent, Belgium.

20 ⁶Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium

21 ⁷Children's Hospital and Medical Center, University of Nebraska, Omaha, Nebraska.

22 ⁸Department of Biomedical Imaging Science, Leeds Institute of Cardiovascular and Metabolic Medicine,
23 University of Leeds, Leeds, United Kingdom.

24 ⁹Consiglio Nazionale delle Ricerche (CNR), Istituto di Fisiologia Clinica, Pisa, Italy.

25 ¹⁰Department of Cardiothoracic Surgery, University of Texas Health Science Center San Antonio, Texas.

26 ¹¹Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.

27 ¹²Division of Cardiovascular Medicine, The Hospital of the University of Pennsylvania, Perelman School
28 of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Philadelphia Adult Congenital
29 Heart Center, The Children's Hospital of Philadelphia, Perelman Center for Advanced Medicine, Penn
30 Medicine, Philadelphia, Pennsylvania.

31 ¹³Cardio-Thoracic and Vascular Department, University Hospital "San Giovanni di Dio e Ruggi
32 d'Aragona," Salerno, Italy.

33 ¹⁴Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno,
34 Baronissi, Italy.

35 ¹⁵Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

36 ¹⁶Division of Human Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio.

37 ¹⁷Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's
38 Hospital/Harvard Medical School, Boston, Massachusetts.

39

40

41

42

43

44

45 Corresponding author:

46 Siddharth Prakash, MD, PhD, Department of Internal Medicine, John P. and Katherine G. McGovern
47 Medical School, University of Texas Health Science Center at Houston, 6431 Fannin Street, MSB 6.116,
48 Houston, Texas, USA

49 E-mail: Siddharth.K.Prakash@uth.tmc.edu; Office: 713-500-7003

50

51 [&]Complete lists of EBAV and BAVCon Investigators are provided in the Acknowledgments.

52 **Abstract**

53 Bicuspid aortic valve (BAV), the most common congenital heart defect, is a major cause
54 of aortic valve disease requiring valve interventions and thoracic aortic aneurysms predisposing
55 to acute aortic dissections. The spectrum of BAV ranges from early onset valve and aortic
56 complications (EBAV) to sporadic late onset disease. Rare genomic copy number variants
57 (CNVs) have previously been implicated in the development of BAV and thoracic aortic
58 aneurysms. We determined the frequency and gene content of rare CNVs in EBAV probands (n
59 = 272) using genome-wide SNP microarray analysis and three complementary CNV detection
60 algorithms (cnvPartition, PennCNV, and QuantiSNP). Unselected control genotypes from the
61 Database of Genotypes and Phenotypes were analyzed using identical methods. We filtered the
62 data to select large genic CNVs that were detected by multiple algorithms. Findings were
63 replicated in cohorts with late onset sporadic disease (n = 5040). We identified 34 large and rare
64 (< 1:1000 in controls) CNVs in EBAV probands. The burden of CNVs intersecting with genes
65 known to cause BAV when mutated was increased in case-control analysis. CNVs intersecting
66 with *GATA4* and *DSCAM* were enriched in cases, recurrent in other datasets, and segregated with
67 disease in families. In total, we identified potentially pathogenic CNVs in 8% of EBAV cases,
68 implicating alterations of candidate genes at these loci in the pathogenesis of BAV.

69 **Author Summary**

70 Bicuspid aortic valve (BAV) is the most common form of congenital heart disease and
71 can lead to long-term complications such as aortic stenosis, aortic regurgitation, or thoracic
72 aortic aneurysms. Most BAV-related complications arise in late adulthood, but 10-15% of
73 individuals with BAV develop early onset complications before age 30. Copy number variants
74 (CNVs) are genomic structural variations that have been previously implicated in some types of
75 congenital heart disease, including BAV. Here we demonstrate that individuals with early onset
76 complications of BAV are enriched for specific rare CNVs compared to individuals with late-
77 onset BAV disease. We also describe novel CNVs involving *DSCAM*, a gene on chromosome 21
78 that has not previously been associated with the development of BAV. These results may lead to
79 improved risk stratification and targeted therapies for BAV patients.

80 **Introduction**

81 Copy number variants (CNVs) have been implicated as causes or modifiers of many
82 human diseases [1]. Specifically, large genomic CNVs are significantly enriched in cohorts with
83 developmental delay or congenital abnormalities, and the severity of phenotypes has been
84 correlated with the burden of rare CNVs [2]. These observations show that large, rare, *de novo*
85 CNVs are likely to be pathogenic and can exert clinically relevant effects on disease
86 pathogenesis [3-4].

87 Congenital heart disease (CHD) has a worldwide prevalence of 8.2 per 1000 live births
88 [5]. CNVs have been implicated in both syndromic and non-syndromic forms of CHD [6-10].
89 The pathogenicity and penetrance of CNVs was initially established for clinical syndromes such
90 as velocardiofacial syndrome, Turner syndrome, or Williams–Beuren syndrome, which involve
91 chromosomal or megabase scale duplications or deletions, but has since been expanded to
92 include additional CHD subtypes [10]. CNVs contribute to 10% of all CHD cases and up to 25%
93 of cases with extracardiac anomalies or other syndromic features [11]. The role of pathogenic
94 CNVs affecting genes that are known to cause CHD when mutated, such as *GATA4* and *TBX1*,
95 has been established [12]. Furthermore, population-level analysis has consistently demonstrated
96 an increased burden of CHD in carriers of CNVs at specific genomic hotspots compared to
97 controls, displaying the pathogenic potential of rare or *de novo* CNVs [12-14].

98 Bicuspid Aortic Valve (BAV) is the most common congenital heart malformation with a
99 population prevalence of 0.5 – 2% [15]. BAV predisposes to aortic valve stenosis and thoracic
100 aortic aneurysms and is associated with other left ventricular outflow tract lesions such as mitral
101 valve disease and coarctation [16]. The high heritability of BAV was demonstrated in first- and

102 second-degree relatives, who are more than ten times more likely to be diagnosed with BAV
103 compared to matched controls [17]. BAV can occur as an isolated congenital lesion or as part of
104 a clinical syndrome. For example, the prevalence of BAV is increased in Velocardiofacial,
105 Loey-Dietz, Kabuki, and Turner syndromes. Pathogenic variants of several genes are
106 implicated in familial non-syndromic BAV, which is typically inherited as an autosomal
107 dominant trait with reduced penetrance and variable expressivity. There is strong cumulative
108 evidence that *GATA4*, *GATA6*, *NOTCH1*, *ROBO4*, *SMAD4*, *MUC4*, and *SMAD6* each contribute
109 to a small percentage of non-syndromic BAV cases. Phenotypic expression of BAV disease
110 ranges from incidental discovery in late adulthood to neonatal or childhood onset of
111 complications. In comparison to patients with later disease onset, younger BAV cohorts tend to
112 present with syndromic features or complex congenital malformations that are more likely to
113 have a genetic cause, thereby increasing the power of association studies to discover clinically
114 relevant CNVs [18]. Recently, we identified recurrent rare CNVs that were enriched for cardiac
115 developmental genes in a young cohort with early-onset thoracic aortic aneurysms or acute aortic
116 dissections [19].

117 We hypothesize that large rare genomic CNVs contribute to early onset complications of
118 BAV. Consistent with previous observations, we predict that the burden and penetrance of rare
119 CNVs will be increased in individuals with early onset disease when compared to elderly
120 sporadic BAV cases and population controls. Identification of novel pathogenic CNVs can
121 provide new insights into the genetic complexity of BAV and may be useful for personalized risk
122 stratification or clinical guidance based on the specific recurrent CNV [20]. Therefore, we set out
123 to describe the burden and penetrance of rare CNVs in a young cohort with early onset
124 complications of BAV disease (EBAV).

125

126 **Materials and Methods**

127 The study protocol was approved by the Committee for the Protection of Human Subjects
128 at the University of Texas Health Science Center at Houston (HSC-MS-11-0185). After written
129 informed consent, we enrolled 272 probands of European ancestry with early onset BAV disease
130 (EBAV), which we defined as individuals with BAV who were under the age of 30 at the time of
131 first clinical event. Clinical events were defined as aortic replacement, aortic valve surgery,
132 aortic dissection, moderate or severe aortic stenosis or aortic regurgitation, large aneurysm ($Z >$
133 4.5), or intervention for BAV-related conditions. Those with hypoplastic left heart, known
134 genetic mutations, genetic syndromes, or complex congenital heart disease were excluded.
135 Affected and unaffected family members of probands were included in this cohort for a total of
136 544 individuals in 293 families (26 trios and 16 multiplex families). Samples were collected and
137 genotyped similar to our previous study [21]. For comparison, we analyzed a cohort of older
138 individuals of European ancestry with sporadic BAV disease selected from the International
139 BAV Consortium (Table 1) [22].

140

141

142

Table 1. Summary of Case Cohorts.

Cohort	Source	Sample Size	Array
EBAV	UTHealth Houston	544	Illumina GSA-24v1.0/2.0
BAVGWAS	International BAV Consortium	5040	Illumina GSA-24v3.0


143 Cohort: name of case cohort; EBAV: family-based cohort selected for early onset complications of bicuspid aortic
144 valve (BAV); BAVGWAS: unrelated probands with sporadic BAV disease. Source: origin of genotypes; Array:
145 microarray used for genotyping.

146

147 Phenotypes were derived from record review with confirmation of image data whenever

148 possible [23-24]. The computational pipeline for CNV analysis of Illumina single nucleotide

149 polymorphism (SNP) array data included three independent CNV detection algorithms (Fig 1).



150

151 **Fig 1. Overview of Pipeline for CNV Identification and Validation.**

152 SNP, single nucleotide polymorphism. QC, Quality control. CNV, copy number variant. The software and
153 algorithms used for the analysis are provided in boxes to the left of the corresponding steps. Illumina raw signal
154 intensity data was trimmed and exported using GenomeStudio. The intensity data was then analyzed with three
155 different CNV calling algorithms (PennCNV [25], cnvPartition, and QuantiSNP [26]) to generate initial CNV calls
156 and sample-level statistics. Sample-level quality control analysis was performed using PennCNV. PLINK [27]
157 toolset was used to define CNV regions from initial CNV calls for subsequent burden testing, enrichment studies,
158 and replication studies. The initial CNV calls were individually screened for CNVs intersecting with candidate loci,
159 which we defined as genes implicated in bicuspid aortic valve disease and those discovered in our enrichment
160 studies. CNVs of interest were then validated in GenomeStudio.

161

162 GenomeStudio was used to exclude samples with indeterminate sex or more than 5%

163 missing genotypes, and single nucleotide polymorphisms (SNPs) with GenTrain = 0. Principal

164 component analysis was used to remove outliers that did not cluster with European ancestry.

165 Only SNPs common to all microarray platforms were included.

166 Three independent algorithms (PennCNV, cnvPartition, and QuantiSNP) were used to
167 generate CNV calls and sample-level quality statistics from SNP intensity data. PennCNV and
168 QuantiSNP were run on Unix clusters and cnvPartition data were exported from GenomeStudio.
169 The analysis was run using default configurations.

170 PennCNV was used to generate QC data and remove CNV calls that intersect with
171 polymorphic genomic regions. Samples that met any of the following criteria were excluded:
172 standard deviation of the LogR ratio (obtained from PennCNV) > 0.35 or number of CNVs > 2
173 standard deviations above the mean for each data set. CNV calls less than 20 kilobase pairs
174 and/or spanned by less than 6 SNP probes were excluded. The overlap function for rare CNVs in
175 PLINK was used to construct CNV regions (CNVRs) and adjacent regions were merged using
176 PennCNV.

177 LogR ratio (LRR) and B allele frequency (BAF) data at CNVRs and calls of interest were
178 visualized in GenomeStudio for validation. For segregation analysis, GenomeStudio was used to
179 determine the presence of CNVs in relatives.

180 A total of 22,014 unselected control Illumina Genotypes obtained from the Database of
181 Genotypes and Phenotypes were analyzed using identical methods (Table in S1Table). Cohorts
182 were paired as follows for case-control analysis based on the concordance of sample-level
183 quality control statistics (mean number of CNV calls and mean standard deviation of the LogR
184 Ratio): EBAV and WLS, BAVGWAS and HRS.

185 PLINK was used to catalog CNV calls and perform burden and enrichment studies. Case
186 - control burden tests were restricted to large (250 - 5000 kilobase pairs), rare (occurring in less
187 than 1 in 1000 samples; total of cases and controls), and validated CNV calls in EBAV probands.
188 Genome Reference Consortium Human Build 37 [28] was used for CNV annotation.

189 Results

190 Compared to BAVGWAS probands, EBAV probands were significantly younger at
 191 diagnosis, had more frequent co-existing congenital heart and vascular lesions, and underwent
 192 more frequent valve or aortic operations. A phenotype summary of the EBAV and BAVGWAS
 193 Cohorts is provided in Table 2.

195 **Table 2. Characteristics of EBAV and BAVGWAS Probands.**

	EBAV (n = 279)	BAVGWAS (n = 3141)
Female (%)	33	29
Age at diagnosis (years)	17 □ 13	52 □ 16
TAA (%)	20	37
Predominant AR (%)	12	40
Predominant AS (%)	20	37
Other Lesions (%)	53	1
Aortic Replacement (%)	27	16
Aortic Valve Surgery (%)	40	16

197 N: number of cases; □, standard deviation; TAA, thoracic aortic aneurysm; AR: aortic regurgitation; AS, aortic
 198 stenosis; Other Lesions, other congenital heart malformations (primarily coarctation or ventricular septal defect). We
 199 had phenotype information for 279 EBAV probands but did not have access to genotype information for all samples.

200
 201 CNV analysis is summarized in Table 3. The percentages of individuals with large and
 202 rare CNV regions were relatively consistent throughout datasets. The prevalence of large and
 203 rare CNVs, specifically large genomic deletions, was increased in EBAV cases compared to
 204 controls (Table S2).

205 **Table 3. Summary of CNV Calls for EBAV Cohort.**

	RATE	p^E	p^B	PROP	p^E	p^B	TOT	p^E	p^B	AVG	p^E	p^B
Large	0.51	1×10^{-7}	1	0.17	1	1	2648	1×10^{-7}	2.2×10^{-2}	690	1×10^{-7}	6×10^{-5}
Rare	0.36	0.79	1	0.21	1	1	426	6.1×10^{-4}	0.87	288	4.1×10^{-2}	0.6
Duplications	7.1×10^{-2}	0.96	1	6.8×10^{-2}	0.96	1	648	0.25	0.98	615	0.18	0.98
Deletions	0.11	1×10^{-7}	1	4.8×10^{-2}	1.9×10^{-2}	1	1477	1.1×10^{-3}	4.1×10^{-2}	608	0.23	1.7×10^{-2}

207 Large: CNV regions between 250 Kb and 5 Mb in length. Rare: occur in fewer than 1 in 1000 individuals; Rate:
 208 number of CNVs per individual; Prop: proportion of samples with one or more CNVs; TOT: total length of all
 209 CNVs in kilobases; AVG: mean CNV length. p^E , p -value for EBAV cohort in respective category. p^B , p -value for

210 BAVGWAS in respective category. Tests are 1-sided with 100,000 permutations. A subset of CNV calls from the
 211 EBAV and BAVGWAS datasets were validated by examining GenomeStudio plots. In total, 125/347 (36%) of
 212 EBAV and 289/600 (48%) of BAVGWAS CNVs were validated.
 213
 214 There were 34 large (>250 Kb), rare (<1:1000 in dbGAP controls) CNV regions that
 215 involved protein-coding genes in EBAV cases (Table S3). Seven of these genic CNVs were
 216 enriched in EBAV cases compared to WLS controls with a genome-wide adjusted empiric $P <$
 217 0.05. These CNVs included the genes *PCP4*, *DSCAM*, *MIR4760*, and *DSCAM-AS1* in 21q22 and
 218 *GATA4*, *C8orf49*, *NEIL2*, *FDFT1*, and *CTSB* in 8p23. Large duplications involving the
 219 Velocardiofacial (VCFS) region in 22q11.2 and 1q21.1 microduplications were also enriched in
 220 EBAV cases (Table S4). The overall burden of large, rare, genic CNVs was not different
 221 between EBAV cases and WLS controls. However, the burden of large, rare genic CNVs
 222 intersecting with genes known to cause BAV when mutated or implicated in syndromic BAV
 223 was significantly increased in EBAV cases (Table 4).

224 **Table 4. Burden Testing of Rare EBAV CNVs.**
 225

	<u>EBAV</u>		<u>WLS</u>		RR	P
	Calls	Rate	Calls	Rate		
Genic	28	0.8	1151	0.65	1.2	0.23
Deletions	11	3.8×10^{-2}	439	4.6×10^{-2}	0.81	0.78
BAV	3	1.0×10^{-2}	1	1.1×10^{-4}	97	1.1×10^{-3}
Total	34	-	1443	-	-	-

226 Calls: total number of CNVs that met the specified criteria. Rate: number of CNVs per individual; RR: relative risk;
 227 P: p-value; Genic: CNVs that intersect with genes; BAV: CNVs that intersect with genes that are known to cause
 228 bicuspid aortic valve (BAV) when mutated or implicated in syndromic BAV. Total: total number of large, rare
 229 CNVs or CNVRs. Tests are 2-sided using 100,000 permutations.
 230

231 We also scrutinized genomic regions that are implicated in CHD by careful analysis of
 232 data from individual CNV algorithms to detect subtle copy number alterations. We identified
 233 additional rare EBAV CNVs that intersect with CHD candidate genes *CELSR1*, *GJA5*, *RAF1*,
 234 *LTBP1*, *KIF1A*, *MYH11*, *MAPK3*, *TTN*, and the VCFS region in 22q11.2. We detected additional
 235 *GATA4* and *DSCAM* CNVs in multiplex families. These CNVs were enriched in EBAV cases
 236 compared to WLS controls (Table 5).

237

Table 5. CNVs Affecting Congenital Heart Disease Genes in EBAV Cohort.

Region	Genes	Case	Control	OR	95% CI
Chr22:46261909-51187440	<i>CELSR1</i>	1	1	33	2.1 to 530
Chr1:146326373-147340734	<i>GJA5</i>	1	2	17	1.5 to 183
Chr3:12599717-12803792	<i>RAF1</i>	1	2	17	1.5 to 183
Chr22:41278694-41813285	<i>DSCAM</i>	4	2	67	12 to 367
Chr8:11495032-11856903	<i>GATA4</i>	4	0	301	16 to 5599
Chr22:19000000-22000000	<i>TBX1, CRKL</i>	4	10	13	4.2 to 43
Chr16:15484868-16295863	<i>MYH11</i>	2	22	3.0	0.70 to 13
Chr2:241652252-241678528	<i>KIF1A</i>	3	22	4.5	1.3 to 15
Chr2:32775984-33331219	<i>LTBP1</i>	2	26	2.5	0.60 to 11

238

Region: coordinates corresponding to the minimum overlap region of CNVs; Genes: cardio-developmental candidate genes in the region. Case: number of large and rare CNVs in EBAV cases that intersect with region of interest. Control: number of CNVs in WLS cohort that intersect with region of interest. OR: odds ratio; 95% CI, 95% confidence interval for respective odds ratio.

239

240

241

242

243

Next, we attempted to replicate our observations by identifying CNVs in the BAVGWAS

244

dataset that overlapped with rare EBAV CNVs. We found that large duplications involving

245

SOX7 and *GATA4* in 8p23 and the VCFS region in 22q11.2 were also significantly enriched in

246

BAVGWAS cases compared to HRS controls (Table 6, Table S6 and S7).

247

248

Table 6. CNVs Affecting Congenital Heart Disease Genes in BAVGWAS Cohort.

Region	Genes	Case	Control	OR	95% CI
Chr3:29993977-31273870	<i>TGFBR2</i>	1	0	5.6	0.23 to 138
Chr9:101861767-102092282	<i>TGFBR1</i>	1	0	5.6	0.23 to 138
Chr21:41577819-41842252	<i>DSCAM</i>	2	1	3.7	0.34 to 41
Chr22:46924254-46931077	<i>CELSR1</i>	3	1	5.6	0.58 to 54
Chr2:111404636-11310378	<i>TMEM87B, FBLN7</i>	3	2	2.8	0.47 to 17
Chr8:11385469-11821835	<i>GATA4</i>	8	1	15	1.9 to 120
Chr12:7918339-8130958	<i>NANOG</i>	10	2	9.4	2.1 to 43
Chr2:147166377-147308112	<i>GJA5</i>	4	10	0.75	0.23 to 2.4
Chr16:29664753-30199713	<i>MAPK3</i>	3	15	0.37	0.11 to 1.3
Chr22:19000000-22000000	<i>TBX1, CRKL</i>	18	11	3.1	1.4 to 6.5
Chr2:32689829-33299434	<i>LTBP1</i>	9	22	0.76	0.35 to 1.7
Chr16:15240816-16281154	<i>MYH11</i>	13	27	0.90	0.46 to 1.7
Chr2:241640262-241689833	<i>KIF1A</i>	13	30	0.81	0.42 to 1.6

249

Region: coordinates corresponding to the minimum overlap region of CNVs; Genes: cardio-developmental candidate genes in the region. Case: number of large and rare CNVs in BAVGWAS cases that intersect with region of interest. Control: number of CNVs in HRS cohort that intersect with region of interest. OR: odds ratio; 95% CI, 95% confidence interval for respective odds ratio.


250

251

252

253

254 CNVs intersecting with *GATA4* and *DSCAM* significantly overlapped between EBAV
 255 and BAVGWAS datasets (Fig 2). On average, the *GATA4* CNVs were larger in the BAVGWAS
 256 dataset while the *DSCAM* CNVs were larger in the EBAV dataset.



264 **Fig 2. UCSC Genome Browser Plots of *GATA4* and *DSCAM* Variants.**

265 (a) Ideogram of Chromosome 8 with view of image in (b) outlined in red box. (b) Plot of *GATA4* variants. Each bar represents a copy number variant (CNV). CNVs from the EBAV cohort are in blue and CNVs from the BAVGWAS cohort are in red. The region spanned by *GATA4* has been highlighted in light blue. (c) Ideogram of Chromosome 21 with view of image in (d) outlined in red box. (d) Plot of *DSCAM* variants. EBAV CNVs are in blue and BAVGWAS CNVs are in red. The region spanned by *DSCAM* is highlighted in light blue. Figures constructed using the UCSC Genome Browser, <http://genome.ucsc.edu> [29].

274 We identified 7 additional CNV regions that are enriched in BAVGWAS cases but not in
 275 EBAV and are rare or absent in controls (Table S5). *NANOG* and *NIBPL* are essential for early

276 heart development, and mutation of *NIBPL* causes Cornelia-de Lange syndrome with a spectrum
277 of congenital heart malformations including BAV.

278 We also identified 21 very large genomic CNVs more than 5 Mb in length in the
279 BAVGWAS dataset. Analysis of GenomeStudio data showed that most of these were mosaic
280 loss of heterozygosity regions or duplications. Nine were large germline chromosome-scale
281 aberrations, including two cases of trisomy 21 (Table S8). We did not identify any large X
282 chromosome copy variants that may be consistent with Turner syndrome. There were no
283 megabase-scale copy number variants in the EBAV dataset.

284 Pedigree analysis showed that several CNVs involving *CELSR1*, *LTBP1*, *KIF1A*, *GATA4*,
285 and *DSCAM* segregate with BAV in EBAV families (Table S9). CNV carriers tended to present
286 due to moderate or severe aortic regurgitation requiring valvular surgery. One proband had aortic
287 coarctation. The youngest age at presentation was 13 years. There were no sex differences in
288 presentation between CNV carriers.

289

290 **Discussion**

291 We identified large, rare, and likely pathogenic CNVs in almost 10% of EBAV probands
292 that are enriched in genes that cause BAV when mutated. The percentage of EBAV cases with
293 likely pathogenic CNVs is similar to our previous observations in a cohort with early onset TAD
294 [30]. Enrichment of CNVs involving *GATA4* and *DSCAM* in EBAV cases replicated in two
295 additional BAV datasets and thousands of unselected control genotypes. This analysis provides
296 compelling evidence that rare CNVs collectively cause more BAV cases than any single mutated
297 gene.

298 GATA-Binding Protein 4 is a transcription factor that is required for cardiac and neuronal
299 differentiation during embryogenesis [31]. Mutations of *GATA4* and its homologs *GATA5* and
300 *GATA6* cause congenital heart lesions [32]. Mutations in the *GATA4* gene have been linked to a
301 range of congenital heart diseases in humans, such as cardiac septal defects, tetralogy of Fallot,
302 and patent ductus arteriosus [33]. Patients with BAV who have rare functional variants in the
303 *GATA* family exhibit varying degrees of aortopathy expression, including aortic aneurysm,
304 dissection, and/or aortic stenosis. Alonso-Montes et al. described 4 predicted deleterious *GATA4*
305 mutations in 122 non-syndromic BAV probands who did not have affected relatives [34]. Rare
306 *GATA4* deletions and putative loss of function mutations are also implicated in CHD with
307 distinctive features, underlining the importance of *GATA4* dosage to cardiac development [35-
308 36]. Glessner et al. discovered large *de novo* (~4Mb) duplications involving *GATA4* in CHD trios
309 with conotruncal defects or left ventricular outflow tract obstructive lesions [37]. Some
310 duplications were inherited from apparently unaffected parents. Zogopoulos and Yu described
311 similar genomic duplications in unaffected individuals and in unselected control genotypes [38-
312 39].

313 These observations are consistent with low-penetrance CHD in *GATA4* duplication
314 carriers. Similar to other complex and multifactorial disorders, CHD pathogenesis is likely
315 caused by the cumulative impact of multiple CNVs or mutations, each exerting small to
316 moderate effects to collectively disrupt cardiac development. For example, the frequency of
317 congenital heart lesions is increased in individuals with velocardiofacial syndrome who have
318 22q1.2 deletions and a common 12p13.31 duplication involving the *SLC2A3* gene. The *SLC2A3*
319 CNV likely functions as a modifier of the cardiac phenotype associated with 22q11 deletion
320 syndrome, exemplifying a “two-hit” model [40].

321 More than half of patients with Down syndrome have congenital heart malformations due
322 to the interaction of multiple dosage-sensitive CHD genes on chromosome 21 [41-43]. Down
323 syndrome cell adhesion molecule, previously shown to play a critical role in neurogenesis, has
324 also been implicated in the pathophysiology of CHD [44]. Analysis of rare segmental trisomies
325 of chromosome 21 suggested that duplication of *DSCAM* and the contiguous *COL6A1* and
326 *COL6A2* genes may cause septal abnormalities and other Down Syndrome-related CHD lesions,
327 including BAV. Overexpression of *DSCAM* and *COL6A2* causes cardiac malformations in mice
328 [45]. Our findings suggest that rare CNVs involving *DSCAM* may contribute to some non-
329 syndromic BAV cases.

330 Consistent with previous observations, *GATA4* and *DSCAM* CNVs segregated with
331 disease in multiple families, but are not fully penetrant and were detected in some unaffected
332 relatives. Intriguingly, large 22q11.2, *GATA4* and *DSCAM* CNVs were more highly enriched in
333 EBAV than in BAVGWAS cases, suggesting that these CNVs may drive early onset BAV
334 disease. These results are consistent with our observation that pathogenic CNVs involving
335 candidate BAV genes are also enriched in EBAV compared to BAVGWAS cases. Our data
336 suggests that pathogenic CNVs at these loci may predict accelerated disease onset or more severe
337 complications.

338 We also identified recurrent rare CNVs of specific dosage-sensitive regions that affect
339 cardiac developmental genes and are implicated in non-syndromic CHD. Recurrent 1q21.1 distal
340 deletions encompassing *GJA5*, the gene encoding Connexin-40, are associated with CHD lesions
341 including BAV. A study of 807 TOF cases showed significant enrichment of small duplications
342 spanning the *GJA5* gene, providing compelling evidence that it acted as the primary candidate
343 gene, supporting the association of *GJA5* and CHD [31]. Additionally, cardiac abnormalities

344 have been documented in mice with a targeted *GJA5* deletion, implying that haploinsufficiency
345 of *GJA5* might contribute to cardiac defects in individuals affected by 1q21.1 deletions [46].
346 *CELSRI*, a cadherin superfamily member, is mutated in families with BAV and hypoplastic left
347 heart syndrome [47]. *LTBP1* encodes an extracellular matrix protein that regulates TGF-beta and
348 fibrillin and has been implicated in congenital heart lesions [48]. *KIF1A*, encoding a kinesin
349 microtubule transporter, was implicated in a dominant multisystem syndromic disorder with
350 valvular and cardiac defects [49]. Mutation of *MYH11* causes familial thoracic aortic aneurysms
351 and dissections with an increased prevalence of BAV [50]. *TTN* mutations cause dilated
352 cardiomyopathy and are associated with other left-sided congenital lesions [51]. Mutations or
353 copy number changes involving these genes all cause a wide spectrum of penetrance and
354 phenotypic severity, consistent with sensitivity to genetic or clinical modifiers.

355 Our combinatorial analysis method eliminated many CNVs that were detected by single
356 algorithms or did not meet quality control benchmarks. Therefore, our analysis likely
357 underestimated the contribution of rare pathogenic CNVs to BAV. We also recognize that
358 cardiac development involves the complex interaction of many genes. We selectively validated
359 individual CNVs at loci of interest but may have underrepresented CNVs that had no *a priori*
360 relationship with CHD. The apparent penetrance of some CNVs may be less than expected due
361 to missing phenotypic information. The available clinical data was not sufficiently detailed to
362 permit genotype-phenotype correlations with specific CHD clinical features.

363 In conclusion, we identified large rare CNVs in a significant proportion of BAV cases,
364 including a subset of CNVs that may predict early onset complications of BAV disease. These
365 observations add to the evidence that rare CNVs may eventually have clinical utility for risk
366 stratification and personalized disease management.

367 **Acknowledgments**

368 We thank Joana Castillo and Jacqueline Jennings for sample preparation, and Gladys Zapata,
369 Nitesh Mehta, and the Laboratory for Translational Genomics at Baylor College of Medicine for
370 microarray genotyping. This study was supported in part by R01HL137028 (SP). Fig 1 created
371 with BioRender.com.

372 The EBAV Investigators are: Shaine A. Morris, Rita Milewski, Giuseppe Limongelli, Allesandro
373 Della Corte, Laura Perrone, Yuli Y. Kim, Hector Michelena, Maria G. Andreassi, Arturo
374 Evangelista, Denver Sallee, Anji Yetman, Kim McBride, Eduardo Bossone, Rodolfo Citro,
375 Dawn S. Hui, Malenka M. Bissell, Andrea Ballotti, Ilenia Foffa, Margot De Marco, Anthony
376 Caffarelli, Rita Weise, Julie DeBacker, Laura Muino Mosquera, Robbin Cohen, Laura Dos
377 Subira, Justin T. Tretter, Anna Sabe Rotes, Martina Caiazza, Lamia Ait Ali, Francesca
378 Pluchinotta, and Simon C. Body.

379 The BAVCon Investigators are: Simon Body, Alessandro Della Corte, Alessandro Frigiola,
380 Andrea Ballotta, Arturo Evangelista, Betti Giusti, Bo Yang, Carlo de Vincentiis, Dan Gilon,
381 David Messika Zeitoun, Dianna M. Milewicz, Eduardo Bossone, Eric Eisselbacher, Francesca R.
382 Pluchinotta, Giuseppe Limongelli, Gordon S. Huggins, Hector I. Michelena, J. Daniel
383 Muehlschelgel, Kim Eagle, Lasse Folkerson, Malenka M. Bissell, María Brion, Patrick Mathieu,
384 Per Eriksson, Peter Lichtner, Rodolfo Citro, Ronen Durst, Sébastien Thériault, Siddharth K.
385 Prakash, Thoralf M. Sundt, Vicenza Stefano Nistri, Yahn Bossé.

386 **References**

- 387 1. Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and
388 evolution. *Annual review of genomics and human genetics*. 2009;10:451.
- 389 2. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker H,
390 Hamid R, Hannig V, Abdel-Hamid H. A copy number variation morbidity map of developmental
391 delay. *Nature genetics*. 2011 Sep;43(9):838-46.
- 392 3. Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA,
393 McConnell JS, Angle B, Meschino WS, Nezarati MM. Phenotypic heterogeneity of genomic
394 disorders and rare copy-number variants. *New England Journal of Medicine*. 2012 Oct
395 4;367(14):1321-31.
- 396 4. Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: a
397 review. *Journal of neurodevelopmental disorders*. 2010 Dec;2(4):182-209.
- 398 5. Liu, Y., Chen, S., Zühlke, L., Black, G., Choy, M. K., Li, N., & Keavney, B. (2019). Global
399 birth prevalence of congenital heart defects 1970–2017: Updated systematic review and meta-
400 analysis of 260 studies. *International Journal of Epidemiology*, 48(42), 455–463.
- 401 6. Hitz MP, Lemieux-Perreault LP, Marshall C, Feroz-Zada Y, Davies R, Yang SW, Lionel AC,
402 D'Amours G, Lemyre E, Cullum R, Bigras JL. Rare copy number variants contribute to
403 congenital left-sided heart disease.
- 404 7. Warburton D, Ronemus M, Kline J, Jobanputra V, Williams I, Anyane-Yeboah K, Chung W,
405 Yu L, Wong N, Awad D, Yu CY. The contribution of de novo and rare inherited copy number
406 changes to congenital heart disease in an unselected sample of children with conotruncal defects
407 or hypoplastic left heart disease. *Human genetics*. 2014 Jan;133:11-27.
- 408 8. Silversides CK, Lionel AC, Costain G, Merico D, Migita O, Liu B, Yuen T, Rickaby J,
409 Thiruvahindrapuram B, Marshall CR, Scherer SW. Rare copy number variations in adults with
410 tetralogy of Fallot implicate novel risk gene pathways.
- 411 9. Ware SM, Jefferies JL. New genetic insights into congenital heart disease. *Journal of clinical*
412 *& experimental cardiology*. 2012 Jun 6.
- 413 10. Sørensen KM, El-Segaier M, Fernlund E, Errami A, Bouvagnet P, Nehme N, Steensberg J,
414 Hjortdal V, Soller M, Behjati M, Werge T. Screening of congenital heart disease patients using
415 multiplex ligation-dependent probe amplification: Early diagnosis of syndromic patients.
416 *American journal of medical genetics Part A*. 2012 Apr;158(4):720-5.
- 417 11. Lander J, Ware SM. Copy number variation in congenital heart defects. *Current Genetic*
418 *Medicine Reports*. 2014 Sep;2:168-78.

- 419 12. Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M,
420 Harris SE, Goetsch MA, Simpson PM, Bick DP, Broeckel U. Human gene copy number spectra
421 analysis in congenital heart malformations. *Physiological genomics*. 2012 May 1;44(9):518-41.
- 422 13. Kim DS, Kim JH, Burt AA, Crosslin DR, Burnham N, Kim CE, McDonald-McGinn DM,
423 Zackai EH, Nicolson SC, Spray TL, Stanaway IB. Burden of potentially pathologic copy number
424 variants is higher in children with isolated congenital heart disease and significantly impairs
425 covariate-adjusted transplant-free survival. *The Journal of thoracic and cardiovascular surgery*.
426 2016 Apr 1;151(4):1147-51.
- 427 14. Soemedi R, Wilson IJ, Bentham J, Darlay R, Töpf A, Zelenika D, Cosgrove C, Setchfield K,
428 Thornborough C, Granados-Riveron J, Blue GM. Contribution of global rare copy-number
429 variants to the risk of sporadic congenital heart disease. *The American Journal of Human*
430 *Genetics*. 2012 Sep 7;91(3):489-501.
- 431 15. Chandra S, Lang RM, Nicolarsen J, Gayat E, Spencer KT, Mor-Avi V, Hofmann Bowman
432 MA. Bicuspid aortic valve: inter-racial difference in frequency and aortic dimensions. *JACC:*
433 *Cardiovascular Imaging*. 2012 Oct;5(10):981-9.
- 434 16. Michelena HI, Prakash SK, Della Corte A, Bissell MM, Anavekar N, Mathieu P, Bossé Y,
435 Limongelli G, Bossone E, Benson DW, Lancellotti P. Bicuspid aortic valve: identifying
436 knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve
437 Consortium (BAVCon). *Circulation*. 2014 Jun 24;129(25):2691-704.
- 438 17. Glotzbach JP, Hanson HA, Tonna JE, Horns JJ, McCarty Allen C, Presson AP, Griffin CL,
439 Zak M, Sharma V, Tristani-Firouzi M, Selzman CH. Familial Associations of Prevalence and
440 Cause-Specific Mortality for Thoracic Aortic Disease and Bicuspid Aortic Valve in a Large-
441 Population Database. *Circulation*. 2023 Jun 15.
- 442 18. Prakash SK, Yetman A, Bissell MM, Kim YY, Michelena H, Hui DS, Caffarelli A,
443 Andreassi MG, Foffa I, Jennings J, Citro R. Recurrent genomic copy number variants implicate
444 new candidate genes for early onset bicuspid aortic valve disease. *Journal of the American*
445 *College of Cardiology*. 2019 Mar 12;73(9S1):620-.
- 446 19. Prakash S, Kuang SQ, GenTAC Registry Investigators, Regalado E, Guo D, Milewicz D.
447 Recurrent rare genomic copy number variants and bicuspid aortic valve are enriched in early
448 onset thoracic aortic aneurysms and dissections. *PloS one*. 2016 Apr 19;11(4):e0153543.
- 449 20. Balistreri CR, Cavarretta E, Sciarretta S, Frati G. Light on the molecular and cellular
450 mechanisms of bicuspid aortic valve to unveil phenotypic heterogeneity. *Journal of Molecular*
451 *and Cellular Cardiology*. 2019;133: 113–114. Doi:10.1016/j.yjmcc.2019.06.004.
- 452 21. Prakash, S.K., LeMaire, S.A., Guo, D.C., Russell, L., Regalado, E.S., Golabbakhsh, H.,
453 Johnson, R.J., Safi, H.J., Estrera, A.L., Coselli, J.S. and Bray, M.S., 2010. Rare copy number -
454 variants disrupt genes regulating vascular smooth muscle cell adhesion and contractility in
455 sporadic thoracic aortic aneurysms and dissections. *The American Journal of Human*
456 *Genetics*, 87(6), pp.743-756.

- 457 22. Prakash SK, Bossé Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A,
458 Pluchinotta FR, Russo MG, Evangelista A, Benson DW, Body SC. A roadmap to investigate the
459 genetic basis of bicuspid aortic valve and its complications: insights from the International
460 BAVCon (Bicuspid Aortic Valve Consortium). *Journal of the American College of Cardiology*.
461 2014 Aug 26;64(8):832-9.
- 462
- 463 23. PA Harris, R Taylor, R Thielke, J Payne, N Gonzalez, JG. Conde. Research electronic data
464 capture (REDCap) – A metadata-driven methodology and workflow process for providing
465 translational research informatics support. *J Biomed Inform*. 2009 Apr;42(2):377-81.
- 466 24. PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua,
467 F Delacqua, J Kirby, SN Duda, REDCap Consortium, The REDCap consortium. Building an
468 international community of software partners. *J Biomed Inform*. 2019 May 9 [doi:
469 10.1016/j.jbi.2019.103208].
- 470 25. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. PennCNV:
471 an integrated hidden Markov model designed for high-resolution copy number variation
472 detection in whole-genome SNP genotyping data. *Genome research*. 2007 Nov 1;17(11):1665-
473 74.
- 474 26. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS, Seller A, Holmes
475 CC, Ragoussis J. QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and
476 accurately map copy number variation using SNP genotyping data. *Nucleic acids research*. 2007
477 Mar 1;35(6):2013-25.
- 478 27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De
479 Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-
480 based linkage analyses. *The American journal of human genetics*. 2007 Sep 1;81(3):559-75.
- 481 28. Church DM, Schneider VA, Graves T, Auger K, Cunningham F, Bouk N, Chen HC,
482 Agarwala R, McLaren WM, Ritchie GR, Albracht D. Modernizing reference genome assemblies.
483 *PLoS biology*. 2011 Jul 5;9(7):e1001091.
- 484 29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The
485 human genome browser at UCSC. *Genome research*. 2002 Jun 1;12(6):996-1006.
- 486 30. Prakash S, Kuang SQ, GenTAC Registry Investigators, Regalado E, Guo D, Milewicz D.
487 Recurrent rare genomic copy number variants and bicuspid aortic valve are enriched in early
488 onset thoracic aortic aneurysms and dissections. *PloS one*. 2016 Apr 19;11(4):e0153543.
- 489 31. Durocher, D., Charron, F., Warren, R., Schwartz, R. J., Nemer, M. The cardiac transcription
490 factors Nkx2-5 and GATA-4 are mutual cofactors. *EMBO J*. 16: 5687-5696, 1997.
- 491 32. Tremblay M, Sanchez-Ferras O, Bouchard M. GATA transcription factors in development
492 and disease. *Development*. 2018 Oct 15;145(20):dev164384.
- 493 33. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. *Current*
494 *topics in developmental biology*. 2012 Jan 1;100:253-77.

- 495 34. Alonso-Montes C, Martín M, Martínez-Arias L, Coto E, Naves-Díaz M, Morís C, Cannata-
496 Andía JB, Rodríguez I. Variants in cardiac GATA genes associated with bicuspid aortic valve.
497 *European journal of clinical investigation*. 2018 Dec;48(12):e13027.
- 498 35. Pehlivan T, Pober BR, Brueckner M, Garrett S, Slauch R, Van Rheeden R, Wilson DB,
499 Watson MS, Hing AV. GATA4 haploinsufficiency in patients with interstitial deletion of
500 chromosome region 8p23.1 and congenital heart disease. *American journal of medical genetics*.
501 1999 Mar 19;83(3):201-6.
- 502 36. Li RG, Xu YJ, Wang J, Liu XY, Yuan F, Huang RT, Xue S, Li L, Liu H, Li YJ, Qu XK.
503 GATA4 loss-of-function mutation and the congenitally bicuspid aortic valve. *The American*
504 *journal of cardiology*. 2018 Feb.
- 505 37. Glessner JT, Bick AG, Ito K, Homsy JG, Rodriguez-Murillo L, Fromer M, Mazaika E,
506 Vardarajan B, Italia M, Leipzig J, DePalma SR. Increased frequency of de novo copy number
507 variants in congenital heart disease by integrative analysis of single nucleotide polymorphism
508 array and exome sequence data. *Circulation research*. 2014 Oct 24;115(10):884-96.
- 509 38. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, Robidoux F, Laflamme P,
510 Cotterchio M, Greenwood C, Scherer SW. Germ-line DNA copy number variation frequencies in
511 a large North American population. *Human genetics*. 2007 Nov;122:345-53.
- 512 39. Yu S, Zhou XG, Fiedler SD, Brawner SJ, Joyce JM, Liu HY. Cardiac defects are infrequent
513 findings in individuals with 8p23.1 genomic duplications containing GATA4. *Circulation:*
514 *Cardiovascular Genetics*. 2011 Dec;4(6):620-5.
- 515 40. Mlynarski EE, Sheridan MB, Xie M, Guo T, Racedo SE, McDonald-McGinn DM, Gai X,
516 Chow EW, Vorstman J, Swillen A, Devriendt K. Copy-number variation of the glucose
517 transporter gene SLC2A3 and congenital heart defects in the 22q11.2 deletion syndrome. *The*
518 *American Journal of Human Genetics*. 2015 May 7;96(5):753-64.
- 519 41. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ, Saker
520 DM. Population-based study of congenital heart defects in Down syndrome. *American journal of*
521 *medical genetics*. 1998 Nov 16;80(3):213-7.
- 522 42. Paladini D, Tartaglione A, Agangi A, Teodoro A, Forleo F, Borghese A, Martinelli P. The
523 association between congenital heart disease and Down syndrome in prenatal life. *Ultrasound in*
524 *Obstetrics and Gynecology*. 2000 Feb;15(2):104-8.
- 525 43. Laursen HB. Congenital heart disease in Down's syndrome. *Heart*. 1976 Jan 1;38(1):32-8.
- 526 44. Kosaki R, Kosaki K, Matsushima K, Mitsui N, Matsumoto N, Ohashi H. Refining
527 chromosomal region critical for Down syndrome-related heart defects with a case of cryptic
528 21q22.2 duplication. *Congenital anomalies*. 2005 Jun;45(2):62-4.
- 529 45. Grossman TR, Gamliel A, Wessells RJ, Taghli-Lamalle O, Jepsen K, Ocorr K, Korenberg
530 JR, Peterson KL, Rosenfeld MG, Bodmer R, Bier E. Over-expression of DSCAM and COL6A2
531 cooperatively generates congenital heart defects. *PLoS genetics*. 2011 Nov 3;7(11):e1002344.

- 532 46. Gu H, Smith FC, Taffet SM, Delmar M. High incidence of cardiac malformations in
533 connexin40-deficient mice. *Circulation research*. 2003 Aug 8;93(3):201-6.
- 534 47. Theis JL, Niaz T, Sundsbak RS, Fogarty ZC, Bamlet WR, Hagler DJ, et al. CELSR1 Risk
535 Alleles in Familial Bicuspid Aortic Valve and Hypoplastic Left Heart Syndrome. *Circ: Genomic
536 and Precision Medicine*. 2022;15. doi:10.1161/CIRCGEN.121.003523.
- 537 48. Pottie L, Adamo CS, Beyens A, Lütke S, Tapaneeyaphan P, De Clercq A, et al. Bi-allelic
538 premature truncating variants in LTBP1 cause cutis laxa syndrome. *The American Journal of
539 Human Genetics*. 2021;108: 1095–1114. doi:10.1016/j.ajhg.2021.04.016.
- 540 49. Akasaka T, Ocorr K, Lin L, Vogler G, Bodmer R, Grossfeld P. Overexpression of Kif1A in
541 the Developing Drosophila Heart Causes Valvar and Contractility Defects: Implications for
542 Human Congenital Heart Disease. *JCDD*. 2020;7: 22. doi:10.3390/jcdd7020022.
- 543 50. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, Presley C, et al. MYH11 mutations
544 result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II.
545 *Human Molecular Genetics*. 2007;16: 2453–2462. doi:10.1093/hmg/ddm201.
- 546 51. Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D,
547 et.al. Truncations of titin causing dilated cardiomyopathy. *New England Journal of Medicine*.
548 2012;366: 619-628. doi: 10.1056/NEJMoa1110186

549 Supplemental Data

550

Cohort	Study	Samples	Accession	Microarray
WLS	Wisconsin Longitudinal Study on Aging	8969	Phs001157.v1.pl	Illumina HumanOmniExpress-24 v1.1
HRS	Health and Retirement Study	9426	phs000428.v2.pl	Illumina Human Omni2.5-Quad

S1 Table. Summary of Control Cohorts. Cohort, name of control cohort. Study, study from which genotypes were obtained. Samples, number of control samples in each dataset. Accession, Database of Genotypes and Phenotypes accession number. Microarray, Illumina microarray used for genotyping.

	EBAV	BAVGWAS	WLS	HRS
PennCNV	6781	73784	58115	163938
cnvPartition	2289	33640	31148	51794
QuantiSNP	1798	21326	14346	85312
Merged	902	7622	21343	14657
Deletions	610	2772	8170	6770
>5 MB	9	22	9830	6114
Rare	84	579	1443	1372
Rare Deletions	59	181	285	394

551 **S2 Table. Comprehensive CNV Summary.** EBAV, EBAV Cohort including cases and unaffected family members.
552 BAVGWAS, BAVGWAS cohort. WLS, WLS cohort. HRS, HRS cohort. PennCNV, number of CNV calls detected
553 by PennCNV algorithm after quality control. cnvPartition, number of CNV calls detected by cnvPartition algorithm
554 after quality control. QuantiSNP, number of CNVs detected by QuantiSNP algorithm after quality control. Merged,
555 number of CNV regions after merging initial calls. Deletions, number of CNV regions that are deletions. >5 MB,
556 number of CNV regions that are larger than 5 megabases. Rare, number of large (> 250 kilobases and less than 5
557 megabases) CNV regions that occur in less than 1 in 1000 samples based on case-control cohort pairs (EBAV and
558 WLS; BAVGWAS and HRS). R. Del., number of large, rare deletions. All values reflect the total CNV calls and
559 regions prior to validation in GenomeStudio.
560

Chr.	Start BP	Stop BP	Type
1	187296703	187609850	DEL
1	146326373	147340734	DUP
1	79238015	79619893	DEL
1	228625778	228880626	DUP
2	114458921	115208197	DUP
2	4638261	5564549	DUP
3	31901848	32165994	DUP
3	19363589	19813225	DEL
4	84658825	85270309	DUP
5	25468811	25719474	DEL
5	78016365	78286867	DUP
6	95836160	96095769	DEL
8	89353386	89800669	DEL

8	2319555	2585105	DUP
8	4201652	4493979	DUP
8	10111571	10721128	DUP
8	11103895	11856864	DUP
8	9368431	9745798	DUP
8	11448529	11732454	DUP
8	11448529	11808756	DUP
10	134505252	135203544	DEL
12	84108147	84443245	DUP
13	70578273	71593281	DUP
15	32908301	34761123	DEL
16	83302526	84016062	DUP
17	1389	582832	DEL
18	57590566	57955945	DUP
21	41268738	41813285	DUP
21	41268738	41823356	DUP
21	41278694	41823356	DUP
21	41278694	41823356	DUP
22	19580050	20227551	DUP
22	46261909	46931077	DEL
22	48871294	51187440	DEL

561 **S3 Table. Large, Rare Copy Number Variants Identified in the EBAV Cohort.** Chr., Chromosome on which
562 CNV is located. Start BP, start basepair of CNV. Stop BP, stop basepair of CNV. Type, denotes if a CNV is a
563 duplication (DUP) or deletion (DEL) event. All CNVs were validated in GenomeStudio.

Gene(s)	Chr.	Start BP	Stop BP	Type
<i>HYDIN2, NBPF12, LOC728989, NBPF13P, PRKAB2, PDIA3P, FM05, CHD1L, LINC00624, BCL9, ACP6, and GJA5</i>	1	146326373	147340734	DUP
<i>HYDIN2, NBPF12, LOC728989, NBPF13P, PRKAB2, PDIA3P, FM05, CHD1L, LINC00624, BCL9, ACP6, and GJA5*</i>	1	146326373	147229299	DUP
<i>MIR4782, SLC35F5, ACTR3, LOC100499194, and LOC440900*</i>	2	114426115	115208197	DUP
<i>MIR4782, SLC35F5, ACTR3, LOC100499194, and LOC440900*</i>	2	114614021	114732241	DUP
<i>MIR4782, SLC35F5, ACTR3, LOC100499194, and LOC440900*</i>	2	114458921	115208197	DUP
<i>MIR4782, SLC35F5, ACTR3, LOC100499194, and LOC440900</i>	2	114458921	115208197	DUP
<i>TTN, AX746670, TTN-AS1, and MIR548N</i>	2	179364778	179486671	DUP

<i>TTN, AX746670, TTN-AS1, and MIR548N*</i>	2	179395466	179517632	DUP
<i>GATA4, C8orf49, NEIL2, FDFT1, and CTSB</i>	8	11506208	11786255	DUP
<i>GATA4, C8orf49, NEIL2, FDFT1, and CTSB</i>	8	11103895	11856864	DUP
<i>GATA4, C8orf49, NEIL2, FDFT1, and CTSB</i>	8	11448529	11808756	DUP
<i>GATA4, C8orf49, NEIL2, FDFT1, and CTSB</i>	8	11448529	11732454	DUP
<i>PARD3</i>	10	35107733	35284461	DUP
<i>PARD3</i>	10	35107733	35271898	DUP
<i>KLHL1 and ATXN8OS</i>	13	70578273	71593281	DUP
<i>KLHL1 and ATXN8OS*</i>	13	70589082	71548725	DUP
<i>KLHL1 and ATXN8OS*</i>	13	70730307	70773605	DEL
<i>NECAB2</i>	16	83302526	84016062	DUP
<i>NECAB2*</i>	16	83303915	83999565	DUP
<i>PCP4, DSCAM, MIR4760, and DSCAM-AS1</i>	21	41278694	41823356	DUP
<i>PCP4, DSCAM, MIR4760, and DSCAM-AS1</i>	21	41268738	41813285	DUP
<i>PCP4, DSCAM, MIR4760, and DSCAM-AS1</i>	21	41278694	41823356	DUP
<i>PCP4, DSCAM, MIR4760, and DSCAM-AS1</i>	21	41278694	41813285	DUP
<i>PCP4, DSCAM, MIR4760, and DSCAM-AS1</i>	21	41268738	41823356	DUP
<i>TBX1, GNB1L, C22orf29, TXNRD2, COMT, MIR4761, ARVCF, TANGO2, MIR185, DGCR8, MIR3618, MIR1306, TRMT2A, RANBP1, ZDHHC8, LOC388849, LOC284865, and LINC00896</i>	22	19580050	20227551	DUP
<i>TBX1, GNB1L, C22orf29, TXNRD2, COMT, MIR4761, ARVCF, TANGO2, MIR185, DGCR8, MIR3618, MIR1306, TRMT2A, RANBP1, ZDHHC8, LOC388849, LOC284865, LINC00896, RTN4R, and MIR1286</i>	22	18877787	21461607	DUP

564
565
566
567

S4 Table. Rare CNVs Enriched in EBAV Cohort. Gene(s), genes intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP, stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.

568 * Indicates the call was from an unaffected family member.
569

Gene(s)	Chr	Start BP	Stop BP	Type
<i>LOC100507334</i>	2	110852875	111406073	DUP
<i>LOC100507334</i>	2	110982530	112007875	DUP
<i>MIR128-2</i>	3	35775249	35938795	DUP
<i>MIR128-2</i>	3	35775249	35938795	DUP
<i>MIR128-2</i>	3	35785608	35936616	DUP
<i>TMPRSS11E, UGT2B17, UGT2B15, UGT2B10</i>	4	69599357	69712995	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, BC013821, LOC100996325, and CEP72</i>	5	323965	889536	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, and BC013821</i>	5	287907	602256	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, and BC013821</i>	5	310925	548342	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, BC013821, LOC100996325, and CEP72</i>	5	426109	673408	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, BC013821, LOC100996325, and CEP72</i>	5	589727	701920	DUP
<i>AHRR, C5orf55, EXOC3, FLJ00157, AK023178, PP7080, BC013821, LOC100996325, and CEP72</i>	5	589727	701920	DUP
<i>NIPBL</i>	5	36764235	37046626	DUP
<i>NIPBL</i>	5	36805679	37046626	DUP
<i>NIPBL</i>	5	36898424	37046626	DUP
<i>NIPBL</i>	5	36911625	37052624	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8064756	11143272	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8064756	11882065	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8064756	8655355	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8114228	8627839	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8202294	8674049	DUP
<i>SGK223, CLDN23, and MFHAS1</i>	8	8221088	8650456	DUP
<i>CUL5</i>	11	107755731	107965390	DUP
<i>NANOG and NANOGNB</i>	12	7893437	8101326	DUP

<i>NANOG</i> and <i>NANOGNB</i>	12	7918339	8109412	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7942473	8109412	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7942945	8123777	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7942945	8105015	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7945559	8101326	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7945559	8105015	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7945559	8105015	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7945559	8109412	DUP
<i>NANOG</i> and <i>NANOGNB</i>	12	7945559	8130958	DUP
<i>UBE2MP1</i> , <i>LOC283914</i> , <i>LOC146481</i> , and <i>LOC100130700</i>	16	34355747	34740580	DUP
<i>LOC283914</i> and <i>LOC146481</i>	16	34428972	34723621	DUP
<i>LOC283914</i>	16	34433468	34663346	DUP
<i>FAM101B</i> , <i>VPS53</i> , and <i>FAM57A</i>	17	1389	641023	DUP
<i>FAM101B</i> , <i>VPS53</i> , <i>FAM57A</i> , <i>GEMIN4</i> , <i>DQ581337</i> , and <i>DBIL5P</i>	17	225778	906268	DEL
<i>FAM101B</i> , <i>VPS53</i> , <i>FAM57A</i> , and <i>GEMIN4</i>	17	225778	649766	DUP
<i>FAM101B</i> , <i>VPS53</i> , <i>FAM57A</i> , and <i>GEMIN4</i>	17	238906	650372	DUP
<i>FAM101B</i> , <i>VPS53</i> , <i>FAM57A</i> , <i>GEMIN4</i> , <i>DQ581337</i> , and <i>DBIL5P</i>	17	284614	831667	DUP
<i>RYR1</i> , <i>MAP4K1</i> , and <i>EIF3K</i>	19	38683266	39116961	DUP
<i>RYR1</i> , <i>MAP4K1</i> , and <i>EIF3K</i>	19	38976659	39116961	DUP
<i>RYR1</i> , <i>MAP4K1</i> , and <i>EIF3K</i>	19	38993142	39116961	DUP
<i>RYR1</i> , <i>MAP4K1</i> , and <i>EIF3K</i>	19	38993142	39116961	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41349732	41508557	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41350509	41600054	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41354458	41588347	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41386035	41522338	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41386814	41531705	DUP
<i>CYP2A7</i> , <i>CYP2G1P</i> , <i>CYP2B7P1</i> , and <i>CYP2B6</i>	19	41386814	41519306	DUP

570 **S5 Table. Rare CNVs Enriched in BAVGWAS Cohort.** Gene(s), genes intersected by CNV. Chr, chromosome on
571 which each CNV is on. Start BP, start basepair of each CNV. Stop BP, stop basepair of each CNV. Type, denotes if
572 a CNV was a duplication (DUP) or deletion (DEL) event.
573
574

Principal Gene/Regions	Chr.	Start BP	Stop BP	Type
<i>KIF1A</i>	2	241640262	241678528	DUP
<i>KIF1A</i>	2	241640262	241678528	DUP
<i>KIF1A</i>	2	241652252	241678528	DUP
<i>KIF1A*</i>	2	241626057	241702124	DUP
<i>KIF1A*</i>	2	241607616	241702124	DUP
<i>KIF1A*</i>	2	241644718	241709924	DUP
<i>LTBP1</i>	2	32639775	33331219	DUP
<i>LTBP1</i>	2	32775984	33331219	DUP
<i>LTBP1*</i>	2	32633925	33331219	DUP
<i>LTBP1*</i>	2	32633925	33331219	DUP
<i>LTBP1*</i>	2	32639775	33331219	DUP
<i>RAF1</i>	3	12599717	12803792	DUP
<i>FLT4*</i>	5	180019198	180056863	DEL
<i>MICA</i>	6	31360255	31453029	DEL
<i>MICA</i>	6	31360255	31485928	DEL
<i>MICA</i>	6	31360255	31487876	DEL
<i>MICA</i>	6	31360255	31457633	DUP
<i>MICA</i>	6	31361397	31453029	DUP
<i>MICA*</i>	6	31360255	31453029	DEL
<i>MICA*</i>	6	31360255	31453029	DEL
<i>MICA*</i>	6	31360255	31453029	DEL
<i>MICA*</i>	6	31360255	31485928	DEL
<i>MICA*</i>	6	31360255	31485928	DEL
<i>MICA*</i>	6	31360255	31485928	DEL
<i>MICA*</i>	6	31383960	31485928	DEL
<i>MICA*</i>	6	31355260	31453029	DEL
<i>GATA4**</i>	8	11506208	11786255	DUP
<i>GATA4**</i>	8	11506208	11999394	DUP
<i>MUC5B</i>	11	1078312	1300406	DUP
<i>NANOG*</i>	12	7945559	8123777	DUP
<i>MYH11</i>	16	14975292	16295863	DUP
<i>MYH11</i>	16	15484868	18309593	DUP
<i>MAPK3</i>	16	27977483	30174024	DUP
<i>NCOR1</i>	17	15976558	16012829	DUP
<i>DSCAM**</i>	21	41278161	41856480	DUP
<i>DSCAM*</i>	21	41278694	41813285	DUP
<i>22q11*</i>	22	19698129	19883189	DEL
<i>22q11*</i>	22	19682627	19755127	DEL
<i>22q11</i>	22	19701341	19776365	DEL
<i>22q11</i>	22	19701341	19808938	DEL

22q11 22 20742450 21461607 DEL

575 **S5 Table. EBAV CNVs intersecting with Genes of Interest.** Gene/Region, Principal gene or region of interest
 576 intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP,
 577 stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.

578 * Indicates the call was from an unaffected family member.

579 ** Indicates the call was from an affected family member from a multiplex family.

580

Principal Gene/Regions	Chr.	Start BP	Stop BP	Type
<i>GJA5</i>	1	145723645	148343177	DUP
<i>GJA5</i>	1	145723739	148343177	DUP
<i>GJA5</i>	1	145801230	147824365	DUP
<i>GJA5</i>	1	147166377	147308112	DUP
<i>TMEM87B/FBLN7</i>	2	110982530	113103748	DUP
<i>TMEM87B/FBLN8</i>	2	111399346	113103748	DEL
<i>TMEM87B/FBLN9</i>	2	111404636	113215796	DUP
<i>KIF1A</i>	2	241623458	241697884	DUP
<i>KIF1A</i>	2	241623458	241697884	DUP
<i>KIF1A</i>	2	241623458	241698298	DUP
<i>KIF1A</i>	2	241623458	241724479	DUP
<i>KIF1A</i>	2	241626057	241689833	DUP
<i>KIF1A</i>	2	241626057	241689833	DUP
<i>KIF1A</i>	2	241626057	241689833	DUP
<i>KIF1A</i>	2	241626057	241689833	DUP
<i>KIF1A</i>	2	241626057	241689833	DUP
<i>KIF1A</i>	2	241626057	241702124	DUP
<i>KIF1A</i>	2	241626057	241702124	DUP
<i>KIF1A</i>	2	241640262	241689833	DUP
<i>KIF1A</i>	2	241640262	241697773	DUP
<i>LTBP1</i>	2	32619581	33299434	DUP
<i>LTBP1</i>	2	32619581	33331219	DUP
<i>LTBP1</i>	2	32633925	33302342	DUP
<i>LTBP1</i>	2	32633925	33302342	DUP
<i>LTBP1</i>	2	32633925	33331219	DUP
<i>LTBP1</i>	2	32633925	33331219	DUP
<i>LTBP1</i>	2	32633925	33331219	DUP
<i>LTBP1</i>	2	32633925	33369552	DUP
<i>LTBP1</i>	2	32689829	33331219	DUP
<i>RAF1</i>	3	12645681	12739194	DUP
<i>TGFBR2</i>	3	29993977	31273870	DEL
<i>SOX7/GATA4</i>	8	8064756	11882065	DUP
<i>SOX7/GATA4</i>	8	8064756	11882065	DUP
<i>SOX7/GATA4</i>	8	8064756	11882065	DUP

SOX7/GATA4	8	8064756	12009597	DUP
SOX7/GATA4	8	10109379	11987960	DUP
SOX7	8	10587741	10683929	DEL
GATA4	8	10914233	11853596	DUP
GATA4	8	11349186	11821835	DUP
GATA4	8	11385469	11882065	DUP
TGFBR1	9	101861767	102092282	DUP
MYH11	16	14761719	16281154	DUP
MYH11	16	14761719	16315360	DUP
MYH11	16	14975292	16299148	DEL
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16308351	DUP
MYH11	16	14975292	16315360	DUP
MYH11	16	15092120	16291933	DUP
MYH11	16	15125441	16292128	DUP
MYH11	16	15240816	18584353	DUP
MAPK3	16	29647342	30199713	DUP
MAPK4	16	29647342	30199713	DUP
MAPK5	16	29647342	30199713	DUP
DSCAM	21	41254102	41516071	DUP
DSCAM	21	41254456	41536215	DUP
22q11	22	16874656	20241436	DEL
22q11	22	17818807	19002159	DUP
22q11	22	18644702	21726191	DUP
22q11	22	18877787	21461607	DUP
22q11	22	18877787	21461607	DUP
22q11	22	18877787	21028007	DEL
22q11	22	18877787	21804903	DEL
22q11	22	19062020	20264937	DUP
22q11	22	19667336	20329526	DEL
22q11	22	19682627	20233865	DEL
22q11	22	19682627	20262166	DEL
22q11	22	19693418	20264937	DEL
22q11	22	19701341	20300738	DEL
22q11	22	19724224	20300738	DEL
22q11	22	19951816	24298181	DUP
22q11	22	20719325	21726191	DEL

22q11	22	21246902	22702508	DEL
22q11	22	21424414	22015771	DUP
<i>CESLR1</i>	22	45236935	48193505	DEL
<i>CESLR1</i>	22	46751367	47159028	DUP
<i>CESLR1</i>	22	46924254	46931077	DEL

581 **S7 Table. BAVGWAS CNVs intersecting with Genes of Interest.** Gene/Region, Principal gene or region of
 582 interest intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV.
 583 Stop BP, stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.
 584
 585

Chr.	Start BP	Stop BP	Type	Description
2	138066736	143331537	DUP	Mosaic LOH
2	183476298	189945752	DUP	Mosaic LOH
3	143040791	168814375	DUP	Mosaic LOH
3	66206	7768285	DEL	Constitutional
6	148301116	156618923	DEL	Constitutional
7	101355402	106892492	DEL	Mosaic
8	6970806	12525566	DUP	Constitutional
8	170692	11987960	DUP	Constitutional
14	101350298	107283150	DUP	Mosaic LOH
14	71135027	107283150	DUP	Mosaic LOH
15	80465431	88497147	DUP	Mosaic LOH
15	93593528	102150818	DUP	Mosaic LOH
15	22761722	28540261	DEL	Constitutional
17	15175570	22234751	DUP	Mosaic
18	67445173	78010620	DEL	Constitutional
20	31265482	50716159	DEL	Mosaic
20	61098	25829977	DEL	Mosaic
20	31240778	48292606	DEL	Mosaic
20	50320079	62960292	DUP	Constitutional
21	14359894	48099610	DUP	Trisomy 21
21	14359894	48099610	DUP	Trisomy 21

586 **S8 Table. Large Genomic Events in BAVGWAS** Chr., Chromosome CNV on which CNV is located. Start BP,
 587 start base pair of CNV. Stop BP, stop base pair of CNV. Type, denotes if a CNV is a duplication (DUP) or deletion
 588 (DEL) event. Description, denotes if the CNV was a mosaic loss of heterozygosity (Mosaic LOH), loss of
 589 heterozygosity (LOH), mosaic (Mosaic), constitutional (constitutional), or trisomy 21 (Trisomy 21) event.
 590
 591

PROBAND	GENE	SEGREGATES?	WITH CNV	NO CNV	SEX
BAV064	<i>GATA4</i>	Yes	Father*, Paternal Grandfather*	Paternal Grandmother	Female
BAV475	<i>DSCAM</i>	Yes	Sister*	Father	Female
BAV787	<i>CELSR1</i>	Yes	None	Daughter	Female

BAV330	<i>KIF1A</i>	Yes	None	Father	Female
BAV478	<i>KIF1A</i>	Yes	None	Father	Male
BAV829	<i>LTBP1</i>	No	Son, Father	Mother, Brother	Female

592 **S9 Table. Pedigree Information for CNVs that Segregated with Disease.** Proband, identification number of
593 proband with CNV intersecting with gene of interest. Gene, gene of interest intersected by CNV. Segregates?,
594 indicates if the CNV segregated with disease. Family With CNV, family members of proband that were found to
595 have a CNV intersecting with the respective gene. Family Without CNV, family members of proband who were not
596 found to have a CNV intersecting with the respective gene. Family members are listed if their genotype was
597 available for the study. Sex, sex of the proband.
598 *Indicates family members who also have BAV.